TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11687731
Drug: ACE-inhibitor trandolapril
Normalized name: Trandolapril
DrugBank: Trandolapril (DB00519)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ACE-inhibitor trandolapril (4 mg)
Study: 11687731
Drug: Non-dihydropyridinic Ca2+
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-dihydropyridinic Ca2+ channel blocker verapamil (240 mg)
Study: 11687731
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trandolapril (2 mg) and verapamil (180 mg)
Study: 12959316
Drug: Racemic tranylcypromine
Normalized name: Racemic Tranylcypromine
DrugBank: Tranylcypromine (DB00752)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Racemic tranylcypromine (20 mg of the sulphate)
Study: 12959316
Drug: Single enantiomers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single enantiomers of tranylcypromine (10 mg of the sulphate)
Study: 18079431
Drug: Perioperative parecoxib
Normalized name: parecoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Perioperative parecoxib 40 mg
Study: 18079431
Drug: Single preoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single preoperative parecoxib dose
Study: 12584282
Drug: Darbepoetin alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Darbepoetin alfa at doses of 0.45 and 0.75 microg/kg/week
Study: 11041909
Drug: Rofecoxib (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5, 25, or 50 mg combined)
Study: 11041909
Drug: NSAIDs (ibuprofen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAIDs (ibuprofen, diclofenac, or nabumetone combined)
Study: 1377305
Drug: Nitrendipine (morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (morning dosage) 20 mg
Study: 1377305
Drug: Nitrendipine (evening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine (evening dosage) 20 mg
Study: 9389278
Drug: Pethidine 25
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 25 mg
Study: 22577906
Drug: Morphine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 2.5 mg
Study: 31183923
Drug: Prostate-specific antigen
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-specific antigen screening and digital rectal examination
Study: 29486797
Drug: BTH1677 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: BTH1677 (4 mg/kg IV weekly) + bevacizumab (15 mg/kg IV Q3W) + carboplatin (6 mg/mL/min Calvert formula Q3W) + paclitaxel (200 mg/m2 Q3W)
Study: 21316934
Drug: Phytosterol supplementation
Normalized name: phytosterols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phytosterol supplementation (4 g per day via 2 plant sterol-enriched yogurt mini drinks)
Study: 7484282
Drug: Calcium tablets
Normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium tablets 1 g/night
Study: 7484282
Drug: Milk powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk powder containing 1 g of calcium
Study: 7484282
Drug: Calcium tablets
Normalized name: Leucovorin Calcium Tablets
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium tablets 1 g/night and exercise regimen
Study: 2301454
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined drug therapy (propranolol and chlorthalidone) with an educational program on hypertension, dietary and exercise modification.
Study: 7783014
Drug: Implant overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant overdentures
Study: 24972949
Drug: Traditional trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional trivalent split virion vaccine (TIIV)
Study: 24972949
Drug: Virosome-adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virosome-adjuvanted trivalent inactivated influenza vaccine (VATIIV)
Study: 22653877
Drug: L‐AMT
Normalized name: Levomethamphetamine
DrugBank: Levmetamfetamine (DB09571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L‐AMT
Study: 22653877
Drug: L/D‐AMT
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/D‐AMT
Study: 30033159
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg caffeine
Study: 8169187
Drug: 2.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/kg caffeine
Study: 17227904
Drug: Oral cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide (50 mg b.i.d. for 21 days), thalidomide (200 mg/day), and prednisone (50 mg q.o.d.)
Study: 17227904
Drug: Oral cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cyclophosphamide, thalidomide, and prednisone (CTP)
Study: 7657279
Drug: No albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No albumin infusion (Control)
Study: 2663695
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human alpha-interferon-2a, 9 million units intramuscularly three times weekly for 16 weeks, followed by 3 million units three times weekly for an additional 8 weeks if viremic after 16 weeks.
Study: 1151628
Drug: Elixir, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elixir, 0.5 mg digoxin
Study: 1151628
Drug: Rapid dissolution
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapid dissolution tablet, 0.5 mg digoxin
Study: 1151628
Drug: Slow dissolution
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow dissolution tablet, 0.5 mg digoxin
Study: 1151628
Drug: Intravenous administration,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration, 0.5 mg digoxin
Study: 26437761
Drug: Oral sodium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral sodium nitrate (NO donor)
Study: 24521888
Drug: Furazolidone-based quadruple
Normalized name: Furazolidone
DrugBank: Furazolidone (DB00614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Furazolidone-based quadruple therapy (Esomeprazole 20 mg twice daily, furazolidone 100 mg twice daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Study: 24521888
Drug: Levofloxacin-based quadruple
Normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levofloxacin-based quadruple therapy (Esomeprazole 20 mg twice daily, levofloxacin 500 mg daily, amoxicillin 1000 mg twice daily, bismuth salts 150 mg thrice daily for 10 days)
Study: 21248158
Drug: 2 doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 doses of HPV vaccine (Gardasil) for group 1, months 0 and 6
Study: 21248158
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of HPV vaccine (Gardasil) for group 2, months 0, 2, and 6
Study: 21248158
Drug: 3 doses
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3 doses of HPV vaccine (Gardasil) for group 3, months 0, 2, and 6
Study: 18081355
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 400 microg buccally
Study: 18081355
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal tablet (FBT) 400 microg sublingually
Study: 16448525
Drug: Sibutramine 10
Normalized name: sibutramine 10 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sibutramine 10 or 15 mg continuously for 12 months
Study: 14567773
Drug: Raloxifene HCl
Normalized name: raloxifene HCl
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene HCl 60 mg daily
Study: 11375775
Drug: Parathyroid hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parathyroid hormone (PTH) delivered intermittently at low doses
Study: 9758073
Drug: Integrated psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated psychological treatment program (self-help techniques, cognitive behavioral strategies, relaxation, physical exercises)
Study: 9758073
Drug: Integrated psychological
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated psychological treatment program
Study: 8076546
Drug: Intranasal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal oxygen supplementation
Study: 3396490
Drug: No antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotic (controls)
Study: 26548726
Drug: AverTeaX applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AverTeaX applied topically six to eight times daily
Study: 22976217
Drug: Betaine (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine (1.25 g BID)
Study: 18031471
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg daily)
Study: 17013640
Drug: Priming drink
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Priming drink (0.03 g/dl alcohol)
Study: 11258039
Drug: Onion-olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onion-olive oil maceration product (4 capsules daily)
Study: 11258039
Drug: Placebo (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (4 capsules daily)
Study: 29266863
Drug: Nebulized hypertonic
Normalized name: Hydra-Neb
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized hypertonic saline (3% HS) with 2.5 mg salbutamol
Study: 29266863
Drug: Nebulized normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulized normal saline (NS) with 2.5 mg salbutamol
Study: 27439433
Drug: Metformin 2
Normalized name: metformin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 2 g (1 g twice daily) plus lifestyle
Study: 22427815
Drug: SVM3 model
Approvals — FDA: no, EMA: no, PMDA: no
Description: SVM3 model constructed by combination of SVM1 and SVM2
Study: 19625372
Drug: Intensive intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intervention targeting LDL-cholesterol <100 mg/dl, using antiplatelet therapy, and switching protease inhibitor therapy.
Study: 19625372
Drug: Standard intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intervention aiming for LDL-cholesterol <130 mg/dL.
Study: 14993579
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine (0.1 to 0.2 mL subcutaneously injected just before PIV insertion)
Study: 7837398
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg orally
Study: 7837398
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg orally
Study: 7837398
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg intramuscularly
Study: 17191188
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis)
Study: 17191188
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of PDT and intravitreal triamcinolone acetonide
Study: 11398072
Drug: 3.0 mg
Normalized name: TOBRAMYCIN 3.0 mg in 1 mL OPHTHALMIC SOLUTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.0 mg of IL‐4R
Study: 9291263
Drug: Mandibular overdenture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular overdenture supported by two implants with ball attachments
Study: 9291263
Drug: Two implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two implants with an interconnecting bar
Study: 9291263
Drug: Four interconnected
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four interconnected implants
Study: 28612375
Drug: ABVE chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVE chemotherapy and 25.5 Gy of involved field radiotherapy for low-risk HL (P9426)
Study: 28612375
Drug: ABVE-PC chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABVE-PC chemotherapy and 21 Gy of involved region radiotherapy for intermediate and high-risk HL (P9425)
Study: 25434365
Drug: Parecoxib (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parecoxib (40 mg) administered 30 min prior to surgery and every 12 h for 60 h
Study: 25434365
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (control group) administered at corresponding time points
Study: 21592110
Drug: Deferasirox (Exjade),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox (Exjade), average dose 19.4 ± 6.3 mg/kg per day
Study: 19116326
Drug: High polyunsaturated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyunsaturated fat intake (>9.9 g/d) with higher α-tocopherol concentrations
Study: 9246969
Drug: CAPF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAPF chemotherapy alone (control)
Study: 29258541
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron polymaltose (single dose calculated using the Ganzoni formula)
Study: 25683075
Drug: Internet-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based treatment programme (n = 124)
Study: 25683075
Drug: Postal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postal treatment programme (n = 126)
Study: 20026777
Drug: Bivalirudin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalirudin plus a glycoprotein IIb/IIIa inhibitor
Study: 17691578
Drug: Control (medication,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (medication, manicol/beronald, Ca2+ antagonist, citicoline, etc.)
Study: 15338488
Drug: COBRA therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: COBRA therapy (prednisolone, methotrexate, and sulfasalazine)
Study: 11919306
Drug: Enoxaparin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (40 mg subcutaneously daily for 6 to 10 days followed by enoxaparin for another 21 days)
Study: 11919306
Drug: Placebo (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (after initial enoxaparin treatment)
Study: 8087360
Drug: Thiorphan (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiorphan (1.25 mg)
Study: 2697584
Drug: Various drug
Normalized name: VARIOUS DRUG CLASSES IN ATC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various drug combinations
Study: 2697584
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of adriamycin, carmustine, cyclophosphamide, and melphalan
Study: 25323140
Drug: Medication (nortriptyline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (nortriptyline v. venlafaxine)
Study: 21654506
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate (CMH) 200 mg/kg daily for 6 months
Study: 19536164
Drug: Nutritional intervention
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional intervention offered as an adjunct to smoking cessation programmes
Study: 8229908
Drug: Sodium loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium loading (10 g/day)
Study: 21224376
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg BID daily
Study: 11980131
Drug: Allicor 2400
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allicor 2400 mg/day
Study: 11980131
Drug: Kwai 900
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Kwai 900 mg/day
Study: 9481530
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (5 mg elemental zinc in syrup daily for 12 weeks)
Study: 9481530
Drug: Placebo (syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (syrup only)
Study: 25830
Drug: 180 ml
Normalized name: Glutol, 100 g/180 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 ml 100 proof vodka
Study: 25830
Drug: 180 ml
Normalized name: Glutol, 100 g/180 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 ml water
Study: 27912934
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) treatment administered twice daily for 7-21 days, followed by TCM for AECOPD risk window over 28 days.
Study: 27912934
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment administered according to the assigned group.
Study: 27912934
Drug: TCM treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM treatment
Study: 27912934
Drug: Both TCM
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both TCM and conventional treatments
Study: 26241543
Drug: Mucosolvan (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mucosolvan (90 mg/day aerosol + 180 mg/day intravenous for 8 days)
Study: 18262663
Drug: Dopamine D3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopamine D3 receptor antagonism
Study: 18262663
Drug: New compounds
Approvals — FDA: no, EMA: no, PMDA: no
Description: New compounds targeting corticotropin‐releasing factor signalling and the endocannabinoid system
Study: 16603599
Drug: DCb (docetaxel
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCb (docetaxel 75 mg/m(2), carboplatin AUC 6)
Study: 16603599
Drug: MIC/MVP (mitomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MIC/MVP (mitomycin 6 mg/m(2), ifosfamide 3 g/m(2) and cisplatin 50 mg/m(2) or mitomycin 6 mg/m(2), vinblastine 6 mg/m(2) and cisplatin 50 mg/m(2))
Study: 1450706
Drug: Recombinant alpha
Normalized name: Recombinant alpha glucosidase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha interferon (IFN, 3 MU daily for 10 days followed by 3 MU twice/week for 3 months)
Study: 31570394
Drug: AT-527 600
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT-527 600 mg once daily for seven days
Study: 29534063
Drug: Clinical Decision
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical Decision Support (CDS) tool for anticoagulant therapy adherence
Study: 23070486
Drug: Rilonacept (2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rilonacept (2.2 mg/kg, maximum 160 mg) by weekly subcutaneous injection for two 3-month courses
Study: 21073556
Drug: Proton Pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton Pump Inhibitors (PPIs) like omeprazole and esomeprazole
Study: 21073556
Drug: NSAIDs that
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NSAIDs that do not interact with aspirin
Study: 16100136
Drug: Gentamicin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 240 mg IV once daily
Study: 9852390
Drug: GnRHa +
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRHa + add-back therapy (20 microg of ethinyl estradiol with 0.15 mg desogestrel)
Study: 10621763
Drug: Fluoxetine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (up to 60 mg/day)
Study: 2200195
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (radio- and chemotherapy with prospidine)
Study: 2200195
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (vestibular cord cancer stage II)
Study: 31733423
Drug: Teriparatide (TPTD)
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Teriparatide (TPTD) 20 μg, s.c., once daily
Study: 31733423
Drug: Percutaneous vertebroplasty
Normalized name: PERCUTANEOUS INTRODUCER SET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous vertebroplasty (PVP) plus alendronate (70 mg, p.o., once weekly)
Study: 31733423
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of TPTD treatment
Study: 31733423
Drug: Cost of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cost of PVP treatment
Study: 28088167
Drug: ARMS-I (Halo™),
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARMS-I (Halo™), sprayed intra-orally 3 times daily for 75 days
Study: 25449059
Drug: Inhaled tiotropium
Normalized name: tiotropium Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled tiotropium 18 μg once daily for 1 month (n = 10)
Study: 25449059
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment, n = 10)
Study: 23706946
Drug: Pro re
Normalized name: Blistex Pro Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pro re nata dosing
Study: 19080748
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive neurosurgery or intravenous hemostatics
Study: 19080748
Drug: Optimized medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized medical care according to ICH treatment guidelines
Study: 17173226
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg every 6 hours)
Study: 9602314
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (24 Gy in four fractions of 6 Gy)
Study: 2897978
Drug: Suriclone 0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.8 mg
Study: 2897978
Drug: Suriclone 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.2 mg
Study: 2897978
Drug: Suriclone 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suriclone 0.6 mg
Study: 22576074
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg intravenous ketamine